Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseJohannes M. F. G. Aerts, Ben J. H. M. Poorthuis, Cindy van Roomen et al.|Proceedings of the National Academy of Sciences|2008Cited by 725
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Carla E. M. Hollak, Oliver Watkinson et al.|Journal of the American Society of Nephrology|2016Cited by 421
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, Robert J. Desnick, Gabor E. Linthorst et al.|Nephrology Dialysis Transplantation|2009Cited by 366
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Gabor E. Linthorst et al.|Journal of Medical Genetics|2015Cited by 363
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Tarekegn Geberhiwot et al.|Orphanet Journal of Rare Diseases|2015Cited by 345